Why You Need a Strategy, Not a Guess
Binary biotech events are fundamentally different from earnings plays or momentum trades. A PDUFA date doesn’t drift — it explodes. The stock opens 40% higher or 60% lower. There is no stop loss that protects you from an overnight gap. There is no “let me see how it plays out.”
This makes strategy non-negotiable. You need to know before the event: what’s your entry, what’s your sizing, what’s your thesis, and what’s your exit for both outcomes. Every approach below provides that structure.
No strategy eliminates risk in biotech catalyst trading. Every strategy below manages risk differently — some avoid binary events entirely, others embrace them with hedging. Choose the one that matches your risk tolerance and capital.
Strategy 1: The Pre-Catalyst Run
The Pre-Catalyst Run
Binary Risk: NoneMany biotechs begin moving weeks before the catalyst date as traders accumulate positions. The strategy: enter early, ride the run-up, exit before the binary event. You capture the anticipation without the coin-flip.
This works best for stocks with high social buzz and growing volume. Look for increasing options activity, growing short interest, and social media chatter 4–6 weeks before the PDUFA date. The run-up itself can produce 20–40% returns in high-conviction names.
The risk: you leave money on the table if the catalyst is positive. But you also avoid the 60% overnight gap down if it’s negative. For traders who want biotech exposure without binary risk, this is the cleanest approach.
Strategy 2: The Post-Event Fade
The Post-Event Fade
Binary Risk: NoneAfter a positive catalyst, stocks often spike and fade over days as initial euphoria meets profit-taking. The strategy: wait for the event, watch the initial spike, look for exhaustion signs, and short the pullback.
This avoids binary risk entirely since you enter after the outcome is known. The trade is based on market microstructure — retail traders buy the news, institutions who accumulated during the run-up begin distributing. The fade from the spike high to the “settled” price can be 10–20%.
When it fails: when the catalyst is so transformative that buying pressure continues for days. First-in-class approvals in large markets can defy the fade. Watch for analyst upgrades and price target increases as signals that the move has more room.
Strategy 3: The CRL Recovery
The CRL Recovery
Binary Risk: Low (delayed)When a stock crashes 50–70% on a Complete Response Letter, the immediate reaction often overshoots the fundamental damage. The strategy: analyze whether the CRL cites fixable issues, then position for the recovery toward the resubmission PDUFA date.
Not all CRLs are equal. Manufacturing deficiencies and labeling issues are fixable — these companies typically resubmit within 6–12 months and have high approval rates on second review. But CRLs citing efficacy concerns or requests for additional clinical trials are much harder to overcome.
The timeline: 6–18 months. The stock usually bottoms within 2–4 weeks of the CRL, then slowly recovers as the company announces resubmission plans. The second PDUFA creates another binary event, but you’ve entered at a dramatically lower cost basis.
Strategy 4: The Magnitude Approach
The Magnitude Approach
Binary Risk: High (hedged)Ignore direction entirely. Identify catalysts with the highest expected magnitude and use options strategies that profit from large moves in either direction — straddles, strangles, or ratio spreads.
The challenge is implied volatility. Options markets price in expected moves, so you need events where the actual magnitude will exceed the market’s implied move. This is where algorithmic catalyst scoring adds value — if a Bio-Score™ of 165 implies a bigger move than the ATM straddle is pricing, the magnitude trade has positive expected value.
The math: an ATM straddle costs X. If the stock moves more than X in either direction, you profit. The key is finding catalysts where the implied move is underpriced — which happens most often in lesser-known biotechs that don’t have options market maker attention.
Strategy 5: The Portfolio Approach
The Portfolio Approach
Binary Risk: DiversifiedTake small positions across many upcoming catalysts, diversifying binary risk across a portfolio. Over a large number of events, a slight edge in catalyst selection produces consistent returns.
This is how institutional biotech funds operate. No single position is large enough to cause significant portfolio damage. The edge comes from systematically identifying catalysts with positive risk/reward asymmetry — where the upside from approval exceeds the downside from rejection.
Requirements: a ranked catalyst feed, capital to execute at scale (minimum 15–20 positions for meaningful diversification), and discipline to maintain small position sizes even when conviction is high. The portfolio approach turns biotech trading from gambling into a probability game.
Every strategy starts with the same input: knowing which catalysts are coming, how significant they are, and when they’ll happen. The strategy you choose depends on your risk tolerance, capital, and time horizon. But all five require a systematic catalyst intelligence feed — not headlines and hunches.
Related Articles
Every strategy starts with a ranked catalyst feed.
See the Bio-Score™ ranked feed — every upcoming biotech catalyst, scored by predicted volatility magnitude. Wall Street intelligence. Retail pricing.
Open App →